75th SCIENTIFIC SESSIONS CORPORATE SYMPOSIA AT-A-GLANCE

FRIDAY, JUNE 5, 2015:

8:00 a.m. – 1:45 p.m. Turning Words into Action in Type 2 Sponsored by Institute for Medical and Nursing Education, Inc. And International Medical Press Supported by an educational grant from AstraZeneca

Contact: Edwin Odoemelam Phone: +44-207-398-0608 Email: [email protected] Location: Westin Waterfront, Harbor Ballroom

This highly interactive workshop is organized by the Global Partnership for Effective Diabetes Management and is designed for healthcare professionals from around the globe, focusing on the need for early glycemic control to reduce diabetes-related complications, and discussion on how to overcome barriers to achieving goals safely.

6:30 p.m. – 9:30 p.m. 6:30 p.m. – 7:00 p.m. – Registration and Dinner 7:00 p.m. – 9:30 p.m. – Educational Program El Panorama Cambiante Sobre el Tratamiento de la Diabetes Tipo 2 con Insulina (Presentado en Español) Jointly sponsored by University of Texas Southwestern Medical Center and Worldwide Initiative for Diabetes Education Supported by an unrestricted educational grant from Novo Nordisk

Contacts: Mark Vinciguerra, University of Texas Southwestern Medical Center Phone/Email: 214-648-4852; [email protected] Jane Savio, Worldwide Initiative for Diabetes Education Phone/Email: 212-614-4337; [email protected] Location: Westin Boston Waterfront, Harbor Ballroom

Este simposio se enfocará en insulinas y nuevas tendencias en terapias de insulina, como es que están redefiniendo el cuidado de la diabetes tipo 2 hoy en día y que esperanza están aportando para hacer frente a la creciente demanda mundial debido al crecimiento de la diabetes y sus complicaciones.

6:30 p.m. – 9:30 p.m. 6:30 p.m. – 7:00 p.m. – Program Registration and Buffet Dinner 7:00 p.m. – 9:00 p.m. – CME Scientific Program Novel Mechanisms and Advancing Therapeutic Paradigms for Optimizing LDL-Focused Management and Cardioprotection in the Diabetic Patient Sponsored by CMEducation Resources

Updated 5/14/15 (for website)

Supported by an educational grant from Sanofi US-Regeneron

Contact: Milo Falcon Phone: 888-977-1625 Location: Boston Marriott Copley Place, Grand Ballroom G-K

This symposium will discuss novel mechanisms and advancing therapeutic paradigms for optimizing LDL- focused management and cardioprotection in diabetic patients. It will focus on clinical trials, mechanisms of atherosclerotic heart disease, novel LDL targets and therapies, and new translational dimensions of applying advances in LDL reduction to the diabetes population.

6:30 p.m. - 9:30 p.m. 6:30 p.m. – 7:00 p.m. - Dinner 7:00 p.m. – 9:30 p.m. – Program Comprehensive Management of DM - Focus on SGLT2 Inhibitors and Combination Therapy - Emerging Concepts of Renal Effects Provided by Metabolic Endocrine Education Foundation, PESI Inc., and Medtelligence Supported by an educational grant from AstraZeneca

Contact: Chris Archibald Phone: 732-977-5887 Email: [email protected] Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom

The overall objective of this CME program is to describe the management of diabetes, discussing early combination therapy and how to achieve goals safely without hypoglycemia or weight gain. The varied effects of newer agents, including SGLT2 inhibitors and incretin-based therapy (DPP4 inhibitors and GLP1 receptor agonists), and their potential combinations will be evaluated. The efficacy of such approaches in glycemic control, the effects on weight and blood pressure, and emerging information about potential positive effects on renal function will be addressed, providing expert insight on the implications of these findings for the long-term management of diabetes. Faculty: Zachary T. Bloomgarden, MD, Chair, Yehuda Handelsman, MD, Chair, Stefano Del Prato, MD, Lawrence A. Leiter, MD, Matthew R. Weir, MD You may view the Agenda and program information at: http://metabolicfoundation.com/ada2015

SATURDAY, JUNE 6, 2015:

5:30 a.m.- 7:30 a.m. 5:30 a.m. – 6:00 a.m. – Breakfast 6:00 a.m. – 7:30 a.m. – Symposium Clinical Issues in Type 2 Diabetes: Discussions and Debates Around GLP-1 Receptor Agonists Jointly provided by Clinical and Patient Educators Association and Integritas Communications Supported by an educational grant from AstraZeneca

Contact: Barbara Jean Wynne Phone: 201-535-4941

Updated 5/14/15 (for website)

Location: Boston Marriott Copley Place, Grand Ballroom G-K

During this Clinical Issues™ program, experts in diabetes research and patient care will discuss and debate a set of topics related to the potential clinical roles of GLP-1 receptor agonists. Throughout the program, the faculty panel will provide practical consensus recommendations for areas in which published evidence for GLP-1 receptor agonists has only recently emerged.

5:30 a.m.- 7:45 a.m. Insulin-Based Options: Current Treatment Strategies and the Potential Impact of Emerging Options on Patient Outcomes 5:30 a.m. – 5:45 a.m. – Breakfast & Arrivals 5:45 a.m. – 7:45 a.m. – Symposium Sponsored by Global Directions in Medicine, Inc. Supported by an educational grant from Novo Nordisk, Inc.

Contact: Deanna Schuly Email: [email protected] Location: Boston Marriott Copley Place, Grand Ballroom A-F

This symposium is designed to improve clinicians’ awareness of the significance of timely glycemic management and initiating and intensifying insulin treatment when appropriate. The latest evidence- based information on emerging insulin therapy, which may help to achieve glycemic goals with lower risks of hypoglycemia and weight gain, will be reviewed.

5:30 a.m.- 7:45 a.m. Managing the High Risk Patient – LDL and Beyond: Contemporary and Future Approaches Provided by Metabolic Endocrine Education Foundation, PESI Inc., and Medtelligence Supported by educational grants from Amgen, Inc. and Amarin Pharma Inc.

Contact: Chris Archibald Phone: 732-977-5887 Email: [email protected] Location: Westin Boston Waterfront, Harbor Ballroom

Despite the availability of numerous clinical guidelines for the management of lipids to reduce cardiovascular disease (CVD), appropriate application of these guidelines remains low, likely contributing to CVD morbidity and mortality. The overall objectives of this CME program are to examine the prevalence of CVD in the high-risk patient, discuss and contrast guidelines, provide an update on pharmacological strategies to reduce CVD risk, and discuss expert insights into how to apply the lipid management guidelines and applicable treatment target goals to achieve better patient outcomes. Faculty: Yehuda Handelsman, MD, Chair, Lawrence A. Leiter, MD, Jorge Plutzky, MD, James A. Underberg, MD, MS, and Howard S. Weintraub, MD

6:15 p.m. - 8:45 p.m. 6:15 p.m. – 7:00 p.m. – Registration and Dinner 7:00 p.m. – 8:45 p.m. – Symposium

Updated 5/14/15 (for website)

Seeing into the Future: Preventing, Diagnosing and Treating Diabetic Eye Disease Sponsored by FocusCME Supported by educational grants from Regeneron Pharmaceuticals and Allergan, Inc.

Contact: Steven Scrivner Email: [email protected] Location: Boston Marriott Copley Place, Grand Ballroom G-K

The goal of this activity is to reinforce traditional strategies and educate clinicians about new strategies for managing the eye health of patients with diabetes. An emphasis will be placed on the need for enhanced communication with the eye care specialist, as well as a general understanding of the therapeutic options available to aid in patient counseling.

Faculty: John E. Anderson, MD; Ralph A. DeFronzo, MD; John W. Kitchens, MD

6:15 p.m. - 9:00 p.m. 6:15 p.m. – 7:00 p.m. – Registration and Dinner 7:00 p.m. – 9:00 p.m. – Scientific Program Patient-Centered Management of Type 2 Diabetes: A Focus on the Newer Antihyperglycemic Agents Sponsored by Institute for Medical and Nursing Education, Inc. Supported by an educational grant from AstraZeneca

Contact: Katie Fidanza Phone: 404-443-1511 Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom

Current type 2 diabetes mellitus (T2DM) treatment guidelines emphasize individualized glycemic targets and patient-centered treatment regimens. This highly interactive symposium will use standardized patients to demonstrate effective techniques for providing patient-centered T2DM care using newer classes of antihyperglycemic agents, including dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors. Practical, evidence-based recommendations for individualizing therapy in T2DM patients with common comorbidities— cardiovascular disease, chronic kidney disease, or will be featured.

6:15 p.m. - 9:15 p.m. Eighth Annual Gerald J. Friedman Fellows Symposium "Nutrition, Diabetes and Human Health" Sponsored by Tufts University, Friedman School of Nutrition Science and Policy Supported by an educational grant from Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research

Contact: Leonid Poretsky, MD Phone: 212-434-3662 Location: Westin Boston Waterfront, Harbor Ballroom

Since 2000 the Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research has supported the work of 41 research fellows (for details see http://friedmanfellows.com/fellows/). The

Updated 5/14/15 (for website)

8th Annual Friedman Fellows Symposium will have the following program: Oral and poster presentation; A debate titled, “Obesity, Nature and Nurture” with plenary speakers Drs. Jeffrey Flier and Terry Maratos-Flier of . Friedman Fellows will address a variety of issues related to nutrition, diabetes and human health.

6:15 p.m. - 9:15 p.m. Type 2 DM- Emerging Therapeutic Trends in OADs and Insulin Combinations Sponsored by Scripps Health Supported by an educational grant from Sanofi Aventis

Contact: Athena Philis-Tsimikas, MD Phone: 858-678-7077 Location: Boston Marriott Copley Place, Grand Ballroom A-F

This symposium will highlight the latest concepts in the treatment of diabetes and will focus on: • Unmet needs and treatment patterns of patients with type 2 diabetes on basal insulin • Knowledge of new basal insulins in development • Strategies to mitigate identified barriers to basal insulin-mediated glucose control

Symposium to cover: • Latest recommendations for advancing diabetes care o Review 2015 Standards of Care o How do new therapeutic classes fit into the treatment regimen o Interactive case discussions with audience response technology • Emerging basal insulins in development o Review current unmet needs o Overview of agents in development o Recent clinical trial results • Strategies for advancing basal insulin therapy and addressing patient barriers o Combination therapies to optimize control o Interactive case discussions with audience response technology

SUNDAY, JUNE 7, 2015:

5:00 a.m.- 7:45 a.m. 5:00 a.m. – 5:30 a.m. – Registration and Breakfast 5:30 a.m. – 7:45 a.m. – CME Symposium Complementary Treatments to Enhance Insulin Efficacy: Theory and Strategies Sponsored by Joslin Diabetes Center Supported by an educational grant from sanofi-aventis US

Contact: Sherlyn B. Celone Phone: 203-451-3164 Location: Westin Boston Waterfront, Harbor Ballroom

Updated 5/14/15 (for website)

Today’s selection of antidiabetes medications improves efficacy and individualization. Yet our non- specialist colleagues often find the options, combinations and barriers to therapeutic advancement daunting. This program will address combined GLP-1 RA/basal insulin, and help empower specialists to be more effective resources for primary care in achieving optimal glycemic control.

6:45 p.m. - 9:00 p.m. 6:45 p.m. – 7:30 p.m. – Dinner 7:30 p.m. – 9:00 p.m. – Symposium Addressing Postprandial Glucose Excursions in T2DM with Inhaled Insulin Sponsored by MediKinetics Supported by an educational grant from Sanofi

Contact: Katie McGowan Phone: 858-717-2940 Location: Westin Boston Waterfront, Harbor Ballroom

A recently approved inhaled insulin provides a convenient prandial option that does not require multiple daily injections and more closely mimics prandial insulin secretions in healthy adults. The drug-device combination is a dry formulation of human insulin delivered through a small inhaler that is administered at the start of a meal. Join our symposium to learn more!

6:45 p.m. - 9:15 p.m. 6:45 p.m. – 7:15 p.m. – Registration and Dinner 7:15 p.m. – 9:15 p.m. – CME-certified Activity Avoiding “Loss of Chance”….Improving the Screening, Treatment and Referral of Patients with Diabetic Retinopathy Provided by Vindico Medical Education Supported by an educational grant from Genentech, Inc.

Contact: Emily Scully Phone: 856-994-9400 Email: [email protected] Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not identified as needing therapy. In addition to counseling patients on the impact glucose control have on maintaining vision, clinicians should emphasize the need for vision screening among patients with diabetes. Early detection offers the best long-term visual outcomes, and is even more important with a new treatment approved for the management of diabetic retinopathy and another being considered. In this activity, leading endocrinologists and retina specialists will discuss preventive measures that clinicians can take to delay or prevent vision loss in patients with diabetes and review the latest data on treatment options for patients with diabetic eye disease.

7:00 p.m. - 9:30 p.m.

Updated 5/14/15 (for website)

7:00 p.m. – 7:30 p.m. – Registration and Buffet Dinner 7:30 p.m. – 9:30 p.m. – Activity The Evolution of Insulin: Applying the Fundamentals of Insulin Physiology to Build a Better Insulin Sponsored by Creative Educational Concepts, Inc. Supported by an educational grant from Lilly

Contact: Ashley C. Lilly Phone: 859-260-1717 x117 Location: Boston Marriott Copley Place, Grand Ballroom G-K

The goal of this activity is to explore key differences between exogenous insulin administration and normal endogenous insulin physiology to better understand the limitations of current insulin preparations and the need to “build a better insulin.” Expert faculty will examine the metabolic abnormalities and adverse effects associated with exogenous insulin administration resulting from over- insulinization of the peripheral tissues and loss of the normal hepatic to peripheral insulin gradient. Attendees will gain an appreciation of the “evolution” of insulin preparations from discovery to their future in modern medicine.

MONDAY, JUNE 8, 2015:

5:30 a.m. - 7:45 a.m. 5:30 AM – 6:15 AM – Breakfast 6:15 AM – 7:45 AM – Presentation Reducing Residual CVD Risk: Shifting the Cholesterol Conversation Beyond Statin Therapy Sponsored by Creative Educational Concepts, Inc. Supported by an educational grant from Lilly

Contact: Rebecca Weaver Phone: 859-260-1717 Location: Boston Marriott Copley Place, Grand Ballroom G-K

The goal of this interactive activity is to explore the controversies surrounding the new ACC/AHA cholesterol guidelines; examine the evidence and rationale for using non-statin therapies to reach target lipid goals; determine the role and practical impact of CETP inhibition in lipid disorders; and discuss recent clinical trial data with CETP inhibitors currently in development. Attendees will gain an appreciation of the need to “shift the cholesterol conversation” beyond statin therapy in order to reduce residual cardiovascular risk for appropriate patients.

6:45 p.m. – 9:15 p.m. 6:45 p.m. – 7:15 p.m. – Registration and Dinner 7:15 p.m. – 9:15 p.m. – CME-certified Activity Combining Therapeutic Advances with Patient Engagement to Optimize Treatment for Patients with Obesity Provided by Vindico Medical Education Supported by an educational grant from Novo Nordisk

Updated 5/14/15 (for website)

Contact: Emily Scully Phone: 856-994-9400 Email: [email protected] Location: Westin Boston Waterfront, Harbor Ballroom

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. In addition, various medical societies have issued recommendations to guide the use of available treatments for obesity. Obesity is a particularly challenging condition in terms of motivating patients to adhere to behavioral and pharmacologic regimens that in many cases require a lifetime commitment. In the last few years, there has been considerable development in pharmacologic options for managing obesity, requiring clinicians to have a thorough understanding of the efficacy and risks associated with each agent in order to help patients determine the most appropriate medication. In this highly interactive program, leading specialists will summarize the latest guidelines for the management of obesity, discuss how to encourage adherence among patients and review all pharmacologic options for the management of obesity in case presentations that allow learners to manage patients along with the panel.

6:45 p.m. - 9:30 p.m. 6:45 p.m. – 7:15 p.m. – Registration and Dinner 7:15 p.m. – 9:30 p.m. – Symposium CV Outcomes with T2D Agents: Application of New Data and Key Takeaways for Your Type 2 Diabetes Practice Sponsored by Medscape Education Supported by an educational grant from Merck

Contact: Kelly Hanley Phone: 973-670-1861 Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom

This live event will address the following learning objectives: • Identify the rationale for cardiovascular (CV) outcomes trials in patients with type 2 diabetes • Review clinical data related to antihyperglycemic agents and CV outcomes • Assess clinical and practical implications of CV outcomes with antihyperglycemic agents trials

6:45 p.m. - 9:30 p.m. 6:45 p.m. – 7:15 p.m. – Registration and Dinner 7:15 p.m. – 9:30 p.m. – CME-certified Activity A Patient-Centered Approach: Treatment Intensification and HbA1c Management Sponsored by Dannemiller and Spire Learning Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

Contact: Elysa Ripa Phone: 973-753-2438 Location: Boston Marriott Copley Place, Grand Ballroom G-K

Updated 5/14/15 (for website)

This symposium will feature the latest evidence on T2DM treatments recently approved by the FDA. You’ll be provided the most up-to-date information on intensification of anti-hyperglycemic regimens and coordination of care – key learnings to help better address treatment intensification in your diabetes patients. This highly interactive program will use real-world case presentations and small-group learning that will focus on a team-based approach and key challenges in T2DM management. Clinical case examples will focus on incorporating new therapies into diabetes management, and improving patient education and coordination of care. The program will also include a case-based workshop. You’ll leave with the latest on new therapies and treatment intensification, treatment efficacy and safety data, tactics for enhanced patient education to reach HbA1c goals, and coordination of care for patients with T2DM to share with your team.

Updated 5/14/15 (for website)